Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Colorcon
Medtronic
Moodys
Harvard Business School

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 7,520,866

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,520,866
Title:Device and method for treatment of wounds with nitric oxide
Abstract: Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing of the wound and in preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used, for example, to reduce the microbial infection and burden on these wounds, manage exudate secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from about 160 to 400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Additionally, exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation at the wound site and increase collagenase expression to debride necrotic tissue at the wound site. After a first treatment period with high concentration of nitric oxide, a second treatment period at a lower concentration of nitric oxide preferably ranging from about 5-20 ppm may to provided to restore the balance of nitric oxide and induce collagen expression to aid in the closure of the wound.
Inventor(s): Stenzler; Alex (Long Beach, CA), Miller; Chris C (North Vancouver, CA)
Assignee: Sensormedics Corporation (Yorba Linda, CA) Pulmonox Technologies Corporation (Edmonton, Alberta, CA)
Application Number:11/487,600
Patent Claims:1. A method for wound bed preparation, the method comprising the steps of: diagnosing a wound site of a subject, providing a flow-controlled source of nitric oxide containing gas, debriding necrotic tissue located at the wound site by exposing the wound site, for a treatment period, to a high concentration of exogenous nitric oxide gas from the flow-controlled source of nitric oxide containing gas; and exposing the wound to a low concentration of exogenous nitric oxide gas for a second treatment period sufficient to induce the expression of new collagen.

2. The method of claim 1, further comprising grafting skin onto the wound site.

3. The method of claim 1, wherein during the debriding step, the endogenous expression of collagenase is induced in situ at the wound site.

4. The method of claim 1, wherein the wound site is exposed to the high concentration of exogenous nitric oxide gas for a period of at least 7 hours.

5. The method of claim 1, wherein the wound site is exposed to the high concentration of exogenous nitric oxide gas for a period of at least 48 hours.

6. The method of claim 1, wherein the high concentration of exogenous nitric oxide gas is about 200 ppm.

7. The method of claim 1, wherein the high concentration of exogenous nitric oxide gas is from about 120 ppm to about 400 ppm.

8. The method of claim 1, wherein the low concentration of exogenous nitric oxide gas is from about 5 ppm to about 20 ppm.

9. The method of claim 1, wherein the wound site is exposed to the low concentration of exogenous nitric oxide gas for a period of at least 7 hours.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Boehringer Ingelheim
Johnson and Johnson
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.